 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Rosetta Stock Rises on Reverse Stock Split, Kidney Test Launch, Medicare Coverage of CUP Dx
May 17, 2012
Rosetta Stock Rises on Reverse Stock Split, Kidney Test Launch, Medicare Coverage of CUP Dx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics Licenses Italian Market Rights to miRNA Dx Suite to AXA Diagnostics
September 10, 2009 / Gene Silencing News - After Raising Cash, Rosetta Aims to Restart R&D Efforts, Get Additional Medicare Approvals
October 4, 2012 / Gene Silencing News - Rosetta Publishes Data on Cancer of Unknown Primary Origin Test
May 31, 2012 / Gene Silencing News - After Medicare Nod for CUP Diagnostic, Rosetta Aims to Get Coverage for Other miRNA Tests
May 24, 2012 / Gene Silencing News - Rosetta Issued Notice of Allowance on microRNA Patent Application
April 26, 2012 / Gene Silencing News